Skip to main content
Top
Published in: Journal of Inherited Metabolic Disease 6/2010

01-12-2010 | Advances and Challenges in PKU

The reality of dietary compliance in the management of phenylketonuria

Authors: Anita MacDonald, Hulya Gokmen-Ozel, Margreet van Rijn, Peter Burgard

Published in: Journal of Inherited Metabolic Disease | Issue 6/2010

Login to get access

Abstract

In phenylketonuria (PKU), it is common for blood phenylalanine (Phe) concentrations to be outside optimal target ranges, particularly in teenagers and adults, indicating inadequate compliance. It is well known that significant noncompliance exists, and the situation in PKU would appear no different than other chronic conditions. In PKU, compliance is complex, being subject to diverse definitions, and factors influencing compliance include the nature and nurture of the patient, as well as the inconvenience, cost and availability of dietary treatment. It is also a dynamic process, with many patients changing between a state of compliance and partial and noncompliance. In PKU, compliance has received little rigorous study, and there have been few observational reports identifying barriers and behaviors impacting dietary compliance. Compliance assessment measures remain inadequately defined. The direct assessment of blood Phe concentration is perhaps the best overall measure, but there is no universal agreement about the number of Phe concentrations that should be within target range and frequency or timing of measurement. Although no one strategy for improving compliance is universally effective, and an individualized approach to noncompliance is essential, it is important to have clear evidence about the most effective strategies in achieving long-term dietary adherence in PKU.
Literature
go back to reference Bartels D (2004) Adherence to oral therapy for type 2 diabetes: opportunities for enhancing glycemic control. J Am Acad Nurse Pract 16:8–16CrossRefPubMed Bartels D (2004) Adherence to oral therapy for type 2 diabetes: opportunities for enhancing glycemic control. J Am Acad Nurse Pract 16:8–16CrossRefPubMed
go back to reference Bekhof J, van Spronsen FJ, Crone MR, van Rijn M, Oudshoorn CGM, Verkerk PH (2003) Influence of knowledge of the disease on metabolic control in phenylketonuria. Eur J Pediatr 162:440–442PubMed Bekhof J, van Spronsen FJ, Crone MR, van Rijn M, Oudshoorn CGM, Verkerk PH (2003) Influence of knowledge of the disease on metabolic control in phenylketonuria. Eur J Pediatr 162:440–442PubMed
go back to reference Bilginsoy C, Waitzman N, Leonard CO, Ernst SL (2005) Living with phenylketonuria: perspectives of patients and their families. J Inherit Metab Dis 28:639–649CrossRefPubMed Bilginsoy C, Waitzman N, Leonard CO, Ernst SL (2005) Living with phenylketonuria: perspectives of patients and their families. J Inherit Metab Dis 28:639–649CrossRefPubMed
go back to reference Buist NR, Prince AP, Huntington KL, Tuerck JM, Waggoner DD (1994) A new amino acid mixture permits new approaches to the treatment of phenylketonuria. Acta Paediatr Suppl 407:75–77, Erratum in: Acta Paediatr 1995; 84: 858CrossRefPubMed Buist NR, Prince AP, Huntington KL, Tuerck JM, Waggoner DD (1994) A new amino acid mixture permits new approaches to the treatment of phenylketonuria. Acta Paediatr Suppl 407:75–77, Erratum in: Acta Paediatr 1995; 84: 858CrossRefPubMed
go back to reference Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ (1996) Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 155(Suppl 1):S33–S38CrossRefPubMed Burgard P, Schmidt E, Rupp A, Schneider W, Bremer HJ (1996) Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria. Eur J Pediatr 155(Suppl 1):S33–S38CrossRefPubMed
go back to reference Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefPubMed Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296–1310CrossRefPubMed
go back to reference Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47PubMed Cramer JA, Roy A, Burrell A et al (2008) Medication compliance and persistence: terminology and definitions. Value Health 11:44–47PubMed
go back to reference Crone MR, van Spronsen FJ, Oudshoorn K, Bekhof J, van Rijn G, Verkerk PH (2005) Behavioural factors related to metabolic control in patients with phenylketonuria. J Inherit Metab Dis 28(5):627–637CrossRefPubMed Crone MR, van Spronsen FJ, Oudshoorn K, Bekhof J, van Rijn G, Verkerk PH (2005) Behavioural factors related to metabolic control in patients with phenylketonuria. J Inherit Metab Dis 28(5):627–637CrossRefPubMed
go back to reference Derose SF, Nakahiro RK, Ziel FH (2009) Automated messaging to improve compliance with diabetes test monitoring. Am J Manag Care 15:425–431PubMed Derose SF, Nakahiro RK, Ziel FH (2009) Automated messaging to improve compliance with diabetes test monitoring. Am J Manag Care 15:425–431PubMed
go back to reference Dezii CM (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10:42–45PubMed Dezii CM (2001) Persistence with drug therapy: a practical approach using administrative claims data. Manag Care 10:42–45PubMed
go back to reference Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE (2008) Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Hum Nutr Diet 21:474–485CrossRefPubMed Durham-Shearer SJ, Judd PA, Whelan K, Thomas JE (2008) Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource. J Hum Nutr Diet 21:474–485CrossRefPubMed
go back to reference Evans S, Daly A, Hopkins V, Davies P, MacDonald A (2009) The impact of visual media to encourage low protein cooking in inherited metabolic disorders. J Hum Nutr Diet 22:409–413, Epub 2009 Apr 1CrossRefPubMed Evans S, Daly A, Hopkins V, Davies P, MacDonald A (2009) The impact of visual media to encourage low protein cooking in inherited metabolic disorders. J Hum Nutr Diet 22:409–413, Epub 2009 Apr 1CrossRefPubMed
go back to reference Gokmen Ozel H, Kucukkasap T, Koksal G, et al (2008) Does maternal knowledge impact blood phenylalanine concentrations in Turkish children with phenylketonuria? J Inherit Metab Dis Jun 27; E-pub ahead of print. doi:10.1007/s10545-008-0775-3. Gokmen Ozel H, Kucukkasap T, Koksal G, et al (2008) Does maternal knowledge impact blood phenylalanine concentrations in Turkish children with phenylketonuria? J Inherit Metab Dis Jun 27; E-pub ahead of print. doi:10.​1007/​s10545-008-0775-3.
go back to reference Gokmen-Ozel H, Ahring K, Bélanger-Quintana A et al (2009) Blood phenylalanine control in PKU: a survey of ten European centres. Poster presentation; 11th International Congress of Inborn Errors of Metabolism, 29 August-2 September 2009, San Diego, CA, USA. Mol Genet Metab 98(1-2):30–31 (Abstract) Gokmen-Ozel H, Ahring K, Bélanger-Quintana A et al (2009) Blood phenylalanine control in PKU: a survey of ten European centres. Poster presentation; 11th International Congress of Inborn Errors of Metabolism, 29 August-2 September 2009, San Diego, CA, USA. Mol Genet Metab 98(1-2):30–31 (Abstract)
go back to reference Hayes RB, Taylor WR, Sackett DL (eds) (1979) Compliance in health care. John Hopkins University Press, Baltimore, pp 1–2 Hayes RB, Taylor WR, Sackett DL (eds) (1979) Compliance in health care. John Hopkins University Press, Baltimore, pp 1–2
go back to reference Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev Apr 16(2):CD000011 Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X (2008) Interventions for enhancing medication adherence. Cochrane Database Syst Rev Apr 16(2):CD000011
go back to reference Hearnshaw H, Lindenmeyer A (2006) What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabetes Med 23:720–728CrossRef Hearnshaw H, Lindenmeyer A (2006) What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements. Diabetes Med 23:720–728CrossRef
go back to reference Ipsiroglu OS, Herle M, Spoula E et al (2005) Transcultural pediatrics: compliance and outcome of phenylketonuria patients from families with an immigration background. Wien Klin Wochenschr 117:541–547CrossRefPubMed Ipsiroglu OS, Herle M, Spoula E et al (2005) Transcultural pediatrics: compliance and outcome of phenylketonuria patients from families with an immigration background. Wien Klin Wochenschr 117:541–547CrossRefPubMed
go back to reference Julius RJ, Novitsky MA Jr, Dubin WR (2009) Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 15:34–44CrossRefPubMed Julius RJ, Novitsky MA Jr, Dubin WR (2009) Medication adherence: a review of the literature and implications for clinical practice. J Psychiatr Pract 15:34–44CrossRefPubMed
go back to reference MacDonald A, Rylance G, Hall SK et al (1996) Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child 74:412–417CrossRefPubMed MacDonald A, Rylance G, Hall SK et al (1996) Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child 74:412–417CrossRefPubMed
go back to reference MacDonald A, Rylance GW, Asplin D et al (1998) Does a single plasma phenylalanine predict quality of control in phenylketonuria? Arch Dis Child 78:122–126CrossRefPubMed MacDonald A, Rylance GW, Asplin D et al (1998) Does a single plasma phenylalanine predict quality of control in phenylketonuria? Arch Dis Child 78:122–126CrossRefPubMed
go back to reference MacDonald A, Manji N, Evans S et al (2006a) Home delivery of dietary products in inherited metabolic disorders reduces prescription and dispensing errors. J Hum Nutr Diet 19:375–381CrossRef MacDonald A, Manji N, Evans S et al (2006a) Home delivery of dietary products in inherited metabolic disorders reduces prescription and dispensing errors. J Hum Nutr Diet 19:375–381CrossRef
go back to reference MacDonald A, Lilburn M, Davies P et al (2006b) ‘Ready to drink’ protein substitute is easier for people with phenylketonuria. J Inherit Metab Dis 29:526–531CrossRef MacDonald A, Lilburn M, Davies P et al (2006b) ‘Ready to drink’ protein substitute is easier for people with phenylketonuria. J Inherit Metab Dis 29:526–531CrossRef
go back to reference MacDonald A, Chakrapani A, Hendriksz C et al (2006c) Protein substitute dosage in PKU: how much do young patients need? Arch Dis Child 91:588–593CrossRef MacDonald A, Chakrapani A, Hendriksz C et al (2006c) Protein substitute dosage in PKU: how much do young patients need? Arch Dis Child 91:588–593CrossRef
go back to reference MacDonald A, Davies P, Daly A et al (2008) Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria. J Hum Nutr Diet 21:351–358CrossRefPubMed MacDonald A, Davies P, Daly A et al (2008) Does maternal knowledge and parent education affect blood phenylalanine control in phenylketonuria. J Hum Nutr Diet 21:351–358CrossRefPubMed
go back to reference Olsson GM, Montgomery SM, Alm J (2007) Family conditions and dietary control in phenylketonuria. J Inherit Metab Dis 30:708–715CrossRefPubMed Olsson GM, Montgomery SM, Alm J (2007) Family conditions and dietary control in phenylketonuria. J Inherit Metab Dis 30:708–715CrossRefPubMed
go back to reference van Spronsen FJ, Burgard P (2008) The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis 31:673–679CrossRefPubMed van Spronsen FJ, Burgard P (2008) The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis 31:673–679CrossRefPubMed
go back to reference van Spronsen FJ, van Rijn M, van Dijk T et al (1993) Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing. Pediatrics 92:570–573PubMed van Spronsen FJ, van Rijn M, van Dijk T et al (1993) Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing. Pediatrics 92:570–573PubMed
go back to reference van Spronsen FJ, van Dijk T, Smit GPA et al (1996) Phenylketonuria: Plasma responses to different distributions of the daily phenylalanine allowance over the day. Pediatrics 97:839–844PubMed van Spronsen FJ, van Dijk T, Smit GPA et al (1996) Phenylketonuria: Plasma responses to different distributions of the daily phenylalanine allowance over the day. Pediatrics 97:839–844PubMed
go back to reference Velligan DI, Wang M, Diamond P et al (2007) Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 58:1187–1192CrossRefPubMed Velligan DI, Wang M, Diamond P et al (2007) Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 58:1187–1192CrossRefPubMed
go back to reference Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26:331–42CrossRefPubMed Vermeire E, Hearnshaw H, Van Royen P, Denekens J (2001) Patient adherence to treatment: three decades of research. A comprehensive review. J Clin Pharm Ther 26:331–42CrossRefPubMed
go back to reference Walter JH, White FJ, Hall SK et al (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360:55–57CrossRefPubMed Walter JH, White FJ, Hall SK et al (2002) How practical are recommendations for dietary control in phenylketonuria? Lancet 360:55–57CrossRefPubMed
go back to reference Zeman J, Pijackova A, Behulova J, Urge O, Saligova D, Hyanek J (1996) Intellectual and school performance in adolescents with phenylketonuria according to their dietary compliance. The Czech-Slovak Collaborative Study. Eur J Pediatr 155(Suppl 1):S56–S58 Zeman J, Pijackova A, Behulova J, Urge O, Saligova D, Hyanek J (1996) Intellectual and school performance in adolescents with phenylketonuria according to their dietary compliance. The Czech-Slovak Collaborative Study. Eur J Pediatr 155(Suppl 1):S56–S58
Metadata
Title
The reality of dietary compliance in the management of phenylketonuria
Authors
Anita MacDonald
Hulya Gokmen-Ozel
Margreet van Rijn
Peter Burgard
Publication date
01-12-2010
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 6/2010
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-010-9073-y

Other articles of this Issue 6/2010

Journal of Inherited Metabolic Disease 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.